Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: Review of omalizumab clinical trials.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Adults and adolescents were included in 3 phase 3 omalizumab trials in chronic idiopathic urticaria (CIU): ASTERIA I, ASTERIA II, and GLACIAL.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Ann Allergy Asthma Immunol

Title: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

Publisher: Elsevier BV

ISSN (Electronic): 1534-4436

ISSN (Print): 1081-1206

Publication date (Electronic): April 2017

Volume: 118

Issue: 4

Affiliations

[1 ] Allergy and Asthma Care of Long Island, New York, New York. Electronic address: drsgoldstein@gmail.com.

[2 ] Department of Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania.

[3 ] Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

Article

Publisher Item ID: S1081-1206(17)30104-7

DOI: 10.1016/j.anai.2017.02.003

PubMed ID: 28390587

SO-VID: 3551528f-c16a-4cd5-8dd0-5eff0ade759f

History

Data availability:

Comments

Comment on this article

scite_

Cited by 7

See all cited by